Alnylam Pharmaceuticals (ALNY)
NASDAQ: ALNY · Biotechnology · Cambridge, MA
Our rating: Positive
Positive reaffirmed at $165.00, moderate conviction, October 30, 2026.
Breaks if: Revenue growth falls below 20% year-over-year in any of the next four quarterly reports — against the current 65.2% — indicating the commercial ramp has plateaued well ahead of schedule and the operating-leverage thesis rests on a slower platform than the valuation implies; or free cash flow margin drops below 10% for two consecutive quarters, compared with today's implied 12.6% ($465M on $3.7B), signaling the cost base is expanding faster than the revenue engine. Either condition would shift the view toward Cautious.
Key figures
| Market value | $19.3B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | $2.6B |
| Free cash flow, last 12 months | n/a |
| Price to earnings | 7.3× |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | 126.6% |
| Beta to the S&P 500 | 0.76 |
| Volatility, annualized | 52.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.5B | 16.7% | $15.72 | $271M |
| June 30, 2026 | $1.3B | 66.9% | $1.21 | n/a |
| March 31, 2026 | n/a | n/a | n/a | n/a |
| December 31, 2025 | $1.1B | 84.9% | $0.82 | $194M |
| September 30, 2025 | $1.2B | 149.3% | $2.14 | $285M |
| June 30, 2025 | $774M | 17.3% | $-0.55 | $114M |
| March 31, 2025 | $594M | 20.2% | $-0.14 | −$127M |
| December 31, 2024 | $593M | 34.9% | $-0.65 | −$104M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.71B: Claude 12%, Gemini 35%, Mistral 25%
- Diluted earnings per share are at least $0.82: Claude 62%, Gemini 90%, Mistral 80%
- Free cash flow for the quarter is at least $0.19B: Claude 58%, Gemini 95%, Mistral 70%
17 ledger entries and 57 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.